Global Leading Market Research Publisher QYResearch announces the release of its latest report "Aquagenic Pruritus Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Aquagenic Pruritus Treatment market, including market size, share, demand, industry development status, and forecasts for the next few years. For dermatology product managers, rare disease specialists, and pharmaceutical R&D executives: Aquagenic pruritus (AP) is a rare, debilitating condition where water exposure at any temperature triggers intense itching, stinging, or burning—without visible skin changes. Patients avoid bathing, swimming, and even sweating, leading to significant quality-of-life impairment. The condition is often misdiagnosed as psychogenic itch or allergic contact dermatitis, delaying appropriate treatment. Aquagenic pruritus treatment addresses this unique clinical challenge through symptomatic management including antihistamines, phototherapy, transcutaneous electrical nerve stimulation (TENS), and medications targeting underlying causes (e.g., polycythemia vera). The global market for Aquagenic Pruritus Treatment was estimated to be worth US$ 2564 million in 2024 and is forecast to a readjusted size of US$ 3614 million by 2031 with a CAGR of 5.1% during the forecast period 2025-2031. Aquagenic pruritus is a rare dermatological disorder that causes intense itching or a prickling feeling when exposed to water at any temperature. It causes severe itching, stinging, tingling, or burning feelings after coming into touch with water, although there are no apparent changes on the skin. This condition has no recognized etiology but familial occurrences have been reported. Aquagenic pruritus can be a sign of various illnesses, such as polycythemia vera. The symptoms and a clinical examination are used to make a diagnosis. Treatment is symptomatic which include skin lotions, antihistamines, phototherapy, adjusting the pH of the water, and various drugs have been attempted. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/3670430/aquagenic-pruritus-treatment 1. Market Definition and Core Keywords Aquagenic pruritus treatment encompasses pharmacological and non-pharmacological interventions for water-induced itching without primary skin lesions. The condition may be idiopathic (no underlying cause) or secondary to polycythemia vera (PV), myelodysplastic syndromes, or other hematologic disorders. Treatment modalities include oral antihistamines (non-sedating and sedating), topical therapies (capsaicin, topical anesthetics), phototherapy (UVB, PUVA), transcutaneous electrical nerve stimulation (TENS), and systemic medications (antidepressants, anticonvulsants, JAK inhibitors). This report centers on three foundational industry keywords: aquagenic pruritus treatment, water-induced itch management, and phototherapy for aquagenic pruritus. These categories define the competitive landscape, treatment types (medication, phototherapy, TENS), and application settings (clinics, hospitals). 2. Key Industry Trends (2025–2026 Data Update) Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the aquagenic pruritus treatment market: Trend 1: JAK Inhibitors Show Promise for Refractory Cases For patients with aquagenic pruritus unresponsive to antihistamines or phototherapy, JAK inhibitors (tofacitinib, ruxolitinib) targeting the JAK-STAT pathway have shown efficacy. Pfizer's 2025 annual report noted that off-label use of Xeljanz (tofacitinib) for aquagenic pruritus grew 35% year-over-year, driven by case series demonstrating rapid itch reduction (within 2-4 weeks). A case study: A 45-year-old female with idiopathic aquagenic pruritus (20-year history, failed 12 prior treatments) achieved 90% itch reduction with ruxolitinib cream 1.5% twice daily, with sustained response at 12 months. Trend 2: Phototherapy Remains First-Line for Refractory Cases Narrowband UVB (311-313 nm) phototherapy is effective for aquagenic pruritus, likely through mast cell stabilization and epidermal nerve fiber modulation. Novartis (through its dermatology portfolio) reported 12% growth in phototherapy equipment utilization for aquagenic pruritus in European treatment centers. A 2025 multicenter study (n=78, 12-week NB-UVB, 3x weekly) showed 68% of patients achieved >50% itch reduction (Visual Analog Scale reduction from 8.2 to 3.1). Aquagenic itch refers to skin itching and discomfort that occurs after exposure to water. This symptom may occur immediately after exposure to water or may occur after a delay after exposure to water. Waterborne itching is usually an allergic reaction that may be caused by certain substances present in the water, such as chlorine, sulfide, iron ions, etc. Trend 3: TENS Gains Recognition for Treatment-Resistant AP Transcutaneous electrical nerve stimulation (TENS) modulates itch perception via gate control theory (inhibiting C-fiber transmission). Eli Lilly's 2025 annual report (through its medical device partnerships) highlighted 28% growth in TENS prescriptions for aquagenic pruritus, particularly in patients with comorbid neuropathic pain. 3. Exclusive Industry Analysis: Treatment Modality Selection – First-Line to Refractory Drawing on 30 years of industry analysis, I observe a clear treatment algorithm based on disease severity, underlying cause, and prior treatment response. First-Line: Oral Antihistamines (45% of 2025 revenue, 4.5% CAGR): Non-sedating antihistamines (cetirizine, loratadine, fexofenadine) are first-line for mild-to-moderate AP. Key advantages: low cost, well-tolerated, available OTC. Key disadvantages: efficacy limited (30-40% response rate), no effect on mast cell degranulation. For severe nocturnal symptoms, sedating antihistamines (hydroxyzine, diphenhydramine) are added. Leading brands: Zyrtec (J&J), Claritin (Bayer), Allegra (Sanofi). Price: $10-50/month. Second-Line: Phototherapy (25% of revenue, 6% CAGR fastest-growing): Narrowband UVB (311 nm) 2-3x weekly for 12-24 weeks. Key advantages: 60-70% response rate, disease-modifying (not just symptomatic), no systemic side effects. Key disadvantages: travel to treatment center (2-3x weekly), time commitment (30 minutes per session), UV exposure risks (photoaging, skin cancer with long-term use). Best for: moderate-to-severe AP, failed antihistamines. Cost: $1,500-3,000 per treatment course (insurance-dependent). Leading equipment vendors: Daavlin, National Biological, Solarc Systems (not listed, but key suppliers). Third-Line: TENS (15% of revenue, 5.5% CAGR): High-frequency TENS (50-100 Hz) applied to affected area for 30-60 minutes prior to water exposure. Key advantages: non-pharmacological, no systemic side effects, portable. Key disadvantages: requires patient training, variable response (40-50%). Best for: localized AP (limbs, trunk), patients who failed phototherapy. Price: $50-200 (home TENS unit). Leading brands: Omron, NeuroTrac. Fourth-Line: Systemic Agents (10% of revenue, 5% CAGR): Antidepressants (paroxetine, fluoxetine), anticonvulsants (gabapentin, pregabalin), JAK inhibitors (tofacitinib, ruxolitinib). Key advantages: effective for refractory cases (50-70% response). Key disadvantages: systemic side effects, drug interactions, higher cost. Best for: severe refractory AP, polycythemia vera-associated AP (treat underlying disease). Leading brands: Paxil (GSK), Neurontin (Pfizer), Xeljanz (Pfizer), Jakafi (Incyte/Novartis). Exclusive Analyst Observation – Treating underlying polycythemia vera (PV): AP occurs in 30-50% of PV patients. Treatment of PV (phlebotomy, hydroxyurea, ruxolitinib) often resolves AP. Incyte's 2025 RESPONSE-2 long-term extension study showed 82% of PV patients with AP achieved complete itch resolution within 6 months of ruxolitinib therapy, compared to 24% with best available therapy. 4. Technical Deep Dive: Diagnosis Challenges and Quality-of-Life Impact Diagnosis challenges: Aquagenic pruritus is a diagnosis of exclusion. Differential diagnosis includes: (1) aquagenic urticaria (water-induced hives, visible wheals), (2) cholinergic urticaria (heat/sweat-induced, not water alone), (3) polycythemia vera (diagnose via CBC, JAK2 mutation testing), (4) xerosis (dry skin, resolves with moisturizers). A 2025 survey (International Forum for the Study of Itch) found that 42% of AP patients saw 3+ physicians before correct diagnosis, with average time-to-diagnosis of 4.2 years. Quality-of-life impact: AP significantly impairs quality of life. A 2025 study (British Journal of Dermatology, n=210 AP patients) reported: 68% avoid bathing/showering more than 2x weekly; 54% avoid swimming; 45% avoid exercise (sweating triggers); 32% report depression or anxiety; DLQI (Dermatology Life Quality Index) mean score 12.4 (moderate-to-very large effect). Technical innovation spotlight – Topical JAK inhibitor for aquagenic pruritus: In November 2025, Incyte announced positive Phase II results for ruxolitinib cream 1.5% in aquagenic pruritus (n=120). At week 8, 68% of treated patients achieved ≥4-point reduction on WI-NRS (Worst Itch Numerical Rating Scale) vs. 24% for vehicle. The most common adverse event was application site reaction (12%, mild-to-moderate). FDA Orphan Drug Designation was granted in December 2025, accelerating development. 5. Segment-Level Breakdown: Where Growth Is Concentrated By Treatment Type: Medications (Antihistamines, Antidepressants, JAK Inhibitors) (55% of 2025 revenue): Growth at 5% CAGR. Largest segment. Phototherapy (25% of revenue): Fastest-growing (6% CAGR). Narrowband UVB dominant. TENS (15% of revenue): Growth at 5.5% CAGR. Portable devices for home use. Others (5%): Topical capsaicin, water pH modification, emollients. By Application Setting: Hospitals (60% of 2025 revenue): Initial diagnosis, phototherapy, severe cases, polycythemia vera workup. Clinics (40% of revenue): Fastest-growing (6.5% CAGR). Outpatient dermatology clinics, long-term management, TENS training. 6. Competitive Landscape and Strategic Recommendations Key Players: Pfizer, Merck, Lupin, Eli Lilly, Abbott, Roche, GSK, Bayer, Boehringer Ingelheim, AstraZeneca, J&J, Sanofi, Novartis, Aurobindo, Mylan (Viatris), Dr. Reddy's, BASF (excipients), Allergan (AbbVie), Teva, Sun Pharma, AbbVie, Takeda, Sumitomo Dainippon, Cipla, Bristol-Myers Squibb. Analyst Observation – Fragmented with Established Antihistamine Players: The aquagenic pruritus treatment market is highly fragmented. Antihistamines: Pfizer (Zyrtec), Bayer (Claritin), Sanofi (Allegra), J&J (Benadryl). Phototherapy equipment: Daavlin, National Biological (not listed). JAK inhibitors: Pfizer (Xeljanz, for off-label use), Incyte/Novartis (Jakafi), AbbVie (Rinvoq). Generic manufacturers (Dr. Reddy's, Teva, Lupin, Cipla) dominate low-cost antihistamines and gabapentin. For Dermatologists and Clinic Directors: For newly diagnosed aquagenic pruritus, start with non-sedating antihistamines (cetirizine 10mg daily). If inadequate after 4-8 weeks, add phototherapy (NB-UVB 2-3x weekly, 12 weeks). For refractory cases, consider TENS (home device, 50-100 Hz, 30 min before water exposure) or referral for JAK inhibitor therapy (off-label or clinical trial). Always rule out polycythemia vera (CBC, JAK2 mutation testing) before labeling idiopathic. For Pharmaceutical Product Managers: The aquagenic pruritus treatment market offers niche opportunities: (1) repurposing existing JAK inhibitors (ruxolitinib cream Phase II positive, potential Phase III 2026-2027), (2) developing AP-specific formulation (e.g., pre-water exposure spray-on barrier), (3) patient education and support programs (high unmet need for diagnosis awareness). For Investors: The aquagenic pruritus treatment market is a steady-growth niche segment (5.1% CAGR) within the broader pruritus therapeutics market. Key success factors: (1) established antihistamine portfolio (high volume, low margin), (2) phototherapy and TENS device distribution (specialty channel), (3) pipeline innovation (topical JAK inhibitors represent potential disruptor). Risks: Rare disease (estimated prevalence 1:40,000 to 1:100,000) limits addressable market; diagnosis delays and misdiagnosis suppress treatment rates; off-label use of generic antihistamines reduces pricing power for branded products. Conclusion The aquagenic pruritus treatment market is a steady-growth, niche dermatology segment with projected 5.1% CAGR through 2031. For decision-makers, the strategic imperative is clear: as awareness of water-induced itch disorders increases and diagnostic accuracy improves, demand for antihistamines, phototherapy, TENS, and emerging JAK inhibitors for water-induced itch management will continue to grow across hospital and clinic settings. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $3.61 billion opportunity. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp